
IRLAB Therapeutics (Q3 review) - Approaching study initiation

Redeye provides a research update following IRLAB's recent Q3 report. While the company reported revenues and a cash position above our estimates, the report did not include any major surprises. We argue that IRLAB's primary focus ahead will be to carry out the upcoming proof-of-concept study with IRL757 and continue its business development efforts regarding mesdopetam and pirepemat.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

IRLAB Therapeutics (Q3 review) - Approaching study initiation